Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Babcock & Wilcox Enterprises, Inc. (“B&W” or the “Company”) (NYSE: BW). Such...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BlackRock, Inc. (“BlackRock” or the “Company”) (NYSE: BLK). Such investors are advised...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Weis Markets, Inc. (“Weis Markets” or the “Company”) (NYSE: WMK). Such investors are...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ingram Micro Holding Corporation (“Ingram” or the “Company”) (NYSE: INGM). Such...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation (“Encompass” or the “Company”) (NYSE: EHC). Such investors...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Apollo Global Management, Inc. (“Apollo” or the “Company”) (NYSE: APO). Such...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Victoria’s Secret & Co. (“Victoria’s Secret” or the “Company”) (NYSE: VSCO). Such...
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GoDaddy Inc. - GDDY
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GoDaddy Inc. (“GoDaddy” or the “Company”) (NYSE: GDDY). Such investors are advised to...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arq, Inc. (“Arq” or the “Company”) (NASDAQ: ARQ). Such investors are advised to contact...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised...